Climb Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(41,793) | $(42,335) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,122 | 7,011 |
| Non-cash operating lease expense | 279 | 144 |
| Accretion of discounts on marketable securities, net | (1,152) | (1,763) |
| Depreciation and amortization expense | 266 | 67 |
| Unrealized foreign currency transaction loss | 7 | 23 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 608 | (110) |
| Other long-term assets | (219) | (1,514) |
| Accounts payable | (1,276) | (228) |
| Accrued expenses and other current liabilities | 1,474 | 152 |
| Operating lease liabilities | (241) | (168) |
| Net cash used in operating activities | (36,925) | (38,721) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (1,080) | (186) |
| Purchases of marketable securities | (164,250) | (103,082) |
| Proceeds from maturities and redemptions of marketable securities | 101,512 | 80,563 |
| Net cash used in investing activities | (63,818) | (22,705) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options and employee stock purchase plan purchases | 1,844 | — |
| Proceeds from the issuance of common stock and pre-funded warrants in private placement, net of issuance costs | 103,368 | — |
| Payment of deferred offering costs | (280) | — |
| Net cash provided by financing activities | 104,932 | — |
| Effect of exchange rate changes on cash and cash equivalents | — | — |
| Net change in cash, cash equivalents and restricted cash | 4,189 | (61,426) |
| Cash, cash equivalents and restricted cash at beginning of period | 35,685 | 87,229 |
| Cash, cash equivalents and restricted cash at end of period | $39,874 | $25,803 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for leases included in operating cash outflows | $195 | $— |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $225 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $1,108 | $216 |
| Decrease in lease liabilities due to reduction in right-of-use assets from lease modifications | $340 | $— |
| Deferred offering costs included in accounts payable and accrued expenses and other current liabilities | $285 | $— |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $39,731 | $25,803 |
| Restricted cash (included in other non-current assets) | 143 | — |
| Total cash, cash equivalents and restricted cash | $39,874 | $25,803 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.